Hetero-Core–Shell BiNS–Fe@Fe as a Potential Theranostic Nanoplatform for Multimodal Imaging-Guided Simultaneous Photothermal–Photodynamic and Chemodynamic Treatment
Source abstract
Abstract
Photothermal/photodynamic therapy (PTT/PDT) and synergistic therapeutic strategies are often sought after, owing to their low side effects and minimal invasiveness compared to chemotherapy and surgical treatments. However, in spite of the development of the most PTT/PDT materials with good tumor-inhibitory effect, there are some disadvantages of photosensitizers and photothermal agents, such as low stability and low photonic efficiency, which greatly limit their further application. Therefore, in this study, a novel bismuth-based hetero-core–shell semiconductor nanomaterial BiNS–Fe@Fe with good photonic stability and synergistic theranostic functions was designed. On the one hand, BiNS–Fe@Fe with a high atomic number exhibits good X-ray absorption, enhanced magnetic resonance (MR) T 2 -weighted imaging, and strong photoacoustic imaging (PAI) signals. In addition, the hetero-core–shell provides a strong barrier to decline the recombination of electron–hole pairs, inducing the generation of a large amount of reactive oxygen species (ROS) when irradiated with visible–NIR light. Meanwhile, a Fenton reaction can further increase ROS generation in the tumor microenvironment. Furthermore, an outstanding chemodynamic therapeutic potential was determined for this material. In particular, a high photothermal conversion efficiency (η = 37.9%) is of significance and could be achieved by manipulating surface decoration with Fe, which results in tumor ablation. In summary, BiNS–Fe@Fe could achieve remarkable utilization of ROS, high photothermal conversion law, and good chemodynamic activity, which highlight the multimodal theranostic potential strategies of tumors, providing a potential viewpoint for theranostic applications of tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Energy, Xiamen University, Xiamen 361002, Fujian, China
Fujian Research Center for Nuclear Engineering, Xiamen 361102, Fujian, China
School of Medicine, Xiamen University, Xiamen 361002, Fujian, China
Department of Oncology, Zhongshan Hospital, Xiamen University, No. 201−209 Hubinnan Road, Xiamen 361004, Fujian, China
174 Clinical College affiliated to Anhui Medical University, Anhui Medical University, Hefei 230032, Anhui, China
Funding
National Natural Science Foundation of China
References (52)
Show source-provided references
1. 10.1016/j.cej.2020.12600810.1016/j.cej.2020.126008 ↗
2. 10.1016/j.cej.2019.12337410.1016/j.cej.2019.123374 ↗
3. 10.1002/smll.20180290410.1002/smll.201802904 ↗
4. 10.1021/acs.nanolett.8b0263910.1021/acs.nanolett.8b02639 ↗
5. 10.1002/anie.20171039910.1002/anie.201710399 ↗
6. 10.1016/j.ceramint.2020.04.17510.1016/j.ceramint.2020.04.175 ↗
7. 10.1039/C9NH00608G10.1039/C9NH00608G ↗
8. 10.1021/acsanm.0c0156310.1021/acsanm.0c01563 ↗
9. 10.1002/adma.20180646110.1002/adma.201806461 ↗
10. 10.1002/adma.20190432910.1002/adma.201904329 ↗
11. 10.1039/C9TB00002J10.1039/C9TB00002J ↗
12. 10.1039/C8NR06812G10.1039/C8NR06812G ↗
13. 10.1016/j.cej.2018.11.21910.1016/j.cej.2018.11.219 ↗
14. 10.1021/acsami.8b0712910.1021/acsami.8b07129 ↗
15. 10.1021/acsami.8b1930410.1021/acsami.8b19304 ↗
16. 10.1002/adfm.20180380410.1002/adfm.201803804 ↗
17. 10.1039/C9CC02677K10.1039/C9CC02677K ↗
18. 10.1038/s41587-019-0262-410.1038/s41587-019-0262-4 ↗
19. 10.1039/C9BM00853E10.1039/C9BM00853E ↗
20. 10.1002/adfm.20180265610.1002/adfm.201802656 ↗
21. 10.1021/acs.nanolett.6b0254710.1021/acs.nanolett.6b02547 ↗
22. 10.1021/acsami.6b1613310.1021/acsami.6b16133 ↗
23. 10.1021/acsami.9b1364710.1021/acsami.9b13647 ↗
24. 10.1002/adma.20170358810.1002/adma.201703588 ↗
25. 10.1002/adma.20190582310.1002/adma.201905823 ↗
26. 10.1021/acsnano.5b0784610.1021/acsnano.5b07846 ↗
27. 10.1016/j.cej.2019.12397910.1016/j.cej.2019.123979 ↗
28. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
29. 10.1016/j.cej.2020.12529410.1016/j.cej.2020.125294 ↗
30. 10.1002/advs.20190137810.1002/advs.201901378 ↗
31. 10.1021/acsami.9b0110710.1021/acsami.9b01107 ↗
32. 10.1021/acsnano.9b0542510.1021/acsnano.9b05425 ↗
33. 10.1016/j.cej.2020.12455510.1016/j.cej.2020.124555 ↗
34. 10.1002/adhm.20150027310.1002/adhm.201500273 ↗
35. 10.1021/acsami.8b2128010.1021/acsami.8b21280 ↗
36. 10.1002/adfm.20200509310.1002/adfm.202005093 ↗
37. 10.1039/D0NR07590F10.1039/D0NR07590F ↗
38. 10.1021/acsnano.9b0646710.1021/acsnano.9b06467 ↗
39. 10.1016/j.biomaterials.2019.11963610.1016/j.biomaterials.2019.119636 ↗
40. 10.1021/acsnano.9b0516910.1021/acsnano.9b05169 ↗
41. 10.1021/acsnano.9b0181810.1021/acsnano.9b01818 ↗
42. 10.1002/adfm.20200032610.1002/adfm.202000326 ↗
43. 10.1016/j.apcatb.2019.03.05510.1016/j.apcatb.2019.03.055 ↗
44. 10.1016/j.seppur.2016.02.02410.1016/j.seppur.2016.02.024 ↗
45. 10.1021/acssuschemeng.7b0303210.1021/acssuschemeng.7b03032 ↗
46. 10.1016/S1872-2067(18)63187-010.1016/S1872-2067(18)63187-0 ↗
47. 10.1021/acsami.9b1035410.1021/acsami.9b10354 ↗
48. 10.1016/j.apcatb.2020.11906310.1016/j.apcatb.2020.119063 ↗
49. 10.1021/acscatal.9b0129810.1021/acscatal.9b01298 ↗
50. 10.1021/acs.jpcc.7b0871110.1021/acs.jpcc.7b08711 ↗
51. 10.1039/C4CP01138D10.1039/C4CP01138D ↗
52. 10.1039/C8NR03054E10.1039/C8NR03054E ↗